Quick Answer
Envoy Medical, Inc. reported Operating Income Loss of -$22.27 million for the year ending 2025.
- Envoy Medical, Inc. showed a decrease of -15.7% in Operating Income Loss from 2024 to 2025.
- This data is from Envoy Medical, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$966.3 thousand | Q2 2021: -$1.07 million | Q3 2021: -$2.99 million | Q1 2022: -$1.49 million | Q2 2022: -$901.4 thousand | Q3 2022: -$1.80 million | Q1 2023: -$3.77 million | Q2 2023: -$4.48 million | Q3 2023: -$3.39 million | Q1 2024: -$4.88 million | Q2 2024: -$4.85 million | Q3 2024: -$4.97 million | Q1 2025: -$5.11 million | Q2 2025: -$5.07 million | Q3 2025: -$5.71 million.
- Over the full 6 years of available data (2020 to 2025), Envoy Medical, Inc.'s Operating Income Loss has declined by 3,176,790.2%.
- Historical annual values: Fiscal year 2025: -$22.27 million | Fiscal year 2024: -$19.26 million | Fiscal year 2023: -$18.36 million | Fiscal year 2022: -$8.71 million | Fiscal year 2021: -$5.20 million | Fiscal year 2020: -$701.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: